Collectively, these findings reveal a complex role of LINC02159 in CRC: while it is upregulated in CRC tissues, higher expression levels correlate with better patient outcomes, suggesting that LINC02159 may serve as a compensatory tumour suppressor specifically in KRASG12D mutated CRC. The gene discussed is LINC02159; the disease is colorectal carcinoma.